Business
Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results
Brii Biosciences Limited ("Brii Bio," "Brii," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical need, today provided a corporate update and reported its financial results for the full year ended December 31, 2025.
About this update from Brii Biosciences Limited
[{"type":"text","content":"Advancing HBV Functional Cure Toward Key Phase 2b Data Readouts","length":63,"tagName":"p","attribs":{}},{"type":"text","content":"Increasing Discovery Efforts to Drive Long-term Value Creation","length":62,"tagName":"p","attribs":{}},{"type":"text","content":"Strong Cash Position Supporting Strategic Priorities ","length":52,"tagName":"p","attribs":{}},{"type":"text","content":"Upcoming Conference Calls: English Session: March 20 at 8:30 p.m. HKT / 8:30 a.m. ET Chinese Session: March 20 at 8:30 a.m. HKT / March 19 at 8:30 p.m. ET","length":166,"tagName":"p"},{"type":"text","content":"DURHAM, N.C. and BEIJING, March 19, 2026 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," "Brii," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical need, today provided a corporate update and reported its financial results for the full year ended December 31, 2025.","length":427,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Brii Biosciences Limited)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Brii Biosciences Limited)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":105,"url":"https://media.zenfs.com/en/prnewswire.com/a19981213a11806c724bc1d308aaae78"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TWMiJ_.KEpuVmmcFLfB56g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE4NQ--/https://media.zenfs.com/en/prnewswire.com/a19981213a11806c724bc1d308aaae78","width":400,"height":105}},"href":"https://mma.prnewswire.com/media/1690538/Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"2025 marked a year of strong execution and strategic progress for Brii Bio, with continued advancement of its late-stage hepatitis B virus (HBV) portfolio toward higher functional cure rates. The Company presented 24-week post end of treatment (EOT) follow-up data from Cohort 4 of its ongoing Phase 2b ENSURE study at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, with simultaneous publication in Nature Medicine. These results support the potential of BRII-179 to improve functional cure outcomes across diverse patient populations. Leveraging insights from the ENSURE Cohort 4, Brii Bio amended the ENHANCE ...